NCT00318136

A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)

A Pilot Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 47 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, single-arm, multicenter pilot study to evaluate the safety and efficacy of carboplatin/paclitaxel+bevacizumab in subjects with locally advanced (Stage IIIb with pleural effusion/pericardial effusion), Stage IV, or recurrent squamous Non-Small Cell Lung Cancer (NSCLC) who have not received prior systemic therapy for metastatic disease.

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Bevacizumab	15 mg/kg administered intravenously on Day 1 of each 21- to 28-day cycle, beginning on Cycle 3
DRUG	Carboplatin	Dose based on Calvert formula, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
DRUG	Paclitaxel	Dose based on patient's body surface area, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles

Timeline

• Start date: 2005-09-01
• Primary completion: 2009-07-01
• Completion: 2009-07-01
• First posted: 2006-04-26
• Last updated: 2010-05-11
• Results posted: 2010-04-06